Normal population
Conditions
Interventions
Case series:NA
Sponsors
Fudan University Shanghai Cancer Center
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.Aged 18-65 years; 2. No positive finding in the EUS examination about the hepatic-biliary-pancreaticosplenic system; 3.Agree to attend this study and sign informed consent.;Inclusion criteria: 1.Aged 18-65 years; 2. No positive finding in the EUS examination about the hepatic-biliary-pancreaticosplenic system; 3.Agree to attend this study and sign informed consent.;Inclusion criteria: 1.Aged 18-65 years; 2. No positive finding in the EUS examination about the hepatic-biliary-pancreaticosplenic system; 3.Agree to attend this study and sign informed consent.;Inclusion criteria: 1.Aged 18-65 years; 2. No positive finding in the EUS examination about the hepatic-biliary-pancreaticosplenic system; 3.Agree to attend this study and sign informed consent.;Inclusion criteria: 1.Aged 18-65 years; 2. No positive finding in the EUS examination about the hepatic-biliary-pancreaticosplenic system; 3.Agree to attend this study and sign informed consent.
Exclusion criteria
Exclusion criteria: 1.Past history of hepatic-biliary-pancreaticosplenic diseases; 2.Abnormal appearance in other imaging modalities about hepatic-biliary-pancreaticosplenic system; 3. Abnormal liver test, tumor markers (CA199, AFP, CA50, CA125); 4. Past history of severe cough, fever, infection in a week, and unstable cardiopulmonary function; 5.History of taking spasmolytic medicine, such as the calcium channel blocker; 6. Pregnant and breas-feeding women; 7.People who attends other clinic trials in resent 3 months; 8.Refuse to assign informed consent.;Exclusion criteria: 1.Past history of hepatic-biliary-pancreaticosplenic diseases; 2.Abnormal appearance in other imaging modalities about hepatic-biliary-pancreaticosplenic system; 3. Abnormal liver test, tumor markers (CA199, AFP, CA50, CA125); 4. Past history of severe cough, fever, infection in a week, and unstable cardiopulmonary function; 5.History of taking spasmolytic medicine, such as the calcium channel blocker; 6. Pregnant and breas-feeding women; 7.People who attends other clinic trials in resent 3 months; 8.Refuse to assign informed consent.;Exclusion criteria: 1.Past history of hepatic-biliary-pancreaticosplenic diseases; 2.Abnormal appearance in other imaging modalities about hepatic-biliary-pancreaticosplenic system; 3. Abnormal liver test, tumor markers (CA199, AFP, CA50, CA125); 4. Past history of severe cough, fever, infection in a week, and unstable cardiopulmonary function; 5.History of taking spasmolytic medicine, such as the calcium channel blocker; 6. Pregnant and breas-feeding women; 7.People who attends other clinic trials in resent 3 months; 8.Refuse to assign informed consent.;Exclusion criteria: 1.Past history of hepatic-biliary-pancreaticosplenic diseases; 2.Abnormal appearance in other imaging modalities about hepatic-biliary-pancreaticosplenic system; 3. Abnormal liver test, tumor markers (CA199, AFP, CA50, CA125); 4. Past history of severe cough, fever, infection in a week, and unstable cardiopulmonary function; 5.History of taking spasmolytic medicine, such as the calcium channel blocker; 6. Pregnant and breas-feeding women; 7.People who attends other clinic trials in resent 3 months; 8.Refuse to assign informed consent.;Exclusion criteria: 1.Past history of hepatic-biliary-pancreaticosplenic diseases; 2.Abnormal appearance in other imaging modalities about hepatic-biliary-pancreaticosplenic system; 3. Abnormal liver test, tumor markers (CA199, AFP, CA50, CA125); 4. Past history of severe cough, fever, infection in a week, and unstable cardiopulmonary function; 5.History of taking spasmolytic medicine, such as the calcium channel blocker; 6. Pregnant and breas-feeding women; 7.People who attends other clinic trials in resent 3 months; 8.Refuse to assign informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Diameter of duodenal papilla(major and minor axis);Diameter of common bile duct;Diameter of cystic duct;Diameter of hepatic duct; | — |
Secondary
| Measure | Time frame |
|---|---|
| Display of common bile duct;Display of cystic duct;Display of hepatic duct; | — |
Countries
China
Contacts
Public ContactYang Xiujiang;Yang Xiujiang;Yang Xiujiang;Yang Xiujiang;Yang Xiujiang ;;;;
Department of Endoscopy, Fudan University Shanghai Cancer Center;Department of Endoscopy, Fudan University Shanghai Cancer Center;Department of Endoscopy, Fudan University Shanghai Cancer Center;Department of Endoscopy, Fudan University Shanghai Cancer Center;Department of Endoscopy, Fudan University Shanghai Cancer Center
Outcome results
None listed